Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robert R Conley

Showing results (71-80 of 113) with videos related to

Pageof 12
Sort By:
BMC Psychiatry|January 12, 2010
The cost of relapse and the predictors of relapse in the treatment of schizophreniaHaya Ascher-Svanum, Baojin Zhu, Douglas E Faries, et al.
Biological Psychiatry|October 22, 2008
Neurotrophin receptor activation and expression in human postmortem brain: effect of suicideYogesh Dwivedi, Hooriyah S Rizavi, Hui Zhang, et al.
Neurochemical Research|June 28, 2008
GSK-3beta gene expression in human postmortem brain: regional distribution, effects of age and suicideGhanshyam N Pandey, Yogesh Dwivedi, Hooriyah S Rizavi, et al.
Schizophrenia Research|October 25, 2011
Responses to antipsychotic therapy among patients with schizophrenia or schizoaffective disorder and either predominant or prominent negative symptomsVirginia L Stauffer, Guochen Song, Bruce J Kinon, et al.
The American Journal of Psychiatry|November 8, 2007
Galantamine for the treatment of cognitive impairments in people with schizophreniaRobert W Buchanan, Robert R Conley, Dwight Dickinson, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|May 28, 2005
Brain region specific alterations in the protein and mRNA levels of protein kinase A subunits in the post-mortem brain of teenage suicide victimsGhanshyam N Pandey, Yogesh Dwivedi, Xinguo Ren, et al.
Schizophrenia Research|February 19, 2008
Quetiapine at high doses for the treatment of refractory schizophreniaDouglas L Boggs, Deanna L Kelly, Stephanie Feldman, et al.
Schizophrenia Research|June 14, 2008
Lack of beneficial galantamine effect for smoking behavior: a double-blind randomized trial in people with schizophreniaDeanna L Kelly, Robert P McMahon, Elaine Weiner, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|December 14, 2007
Lower phosphoinositide 3-kinase (PI 3-kinase) activity and differential expression levels of selective catalytic and regulatory PI 3-kinase subunit isoforms in prefrontal cortex and hippocampus of suicide subjectsYogesh Dwivedi, Hooriyah S Rizavi, Tara Teppen, et al.
Current Medical Research and Opinion|January 27, 2011
Cost-effectiveness of olanzapine long-acting injection in the treatment of patients with schizophrenia in the United States: a micro-simulation economic decision modelNicolas M Furiak, Haya Ascher-Svanum, Robert W Klein, et al.
Pageof 12

Showing results (71-80 of 113) with videos related to

Sort By:
Pageof 12
BMC Psychiatry|January 12, 2010
The cost of relapse and the predictors of relapse in the treatment of schizophreniaHaya Ascher-Svanum, Baojin Zhu, Douglas E Faries, et al.
Biological Psychiatry|October 22, 2008
Neurotrophin receptor activation and expression in human postmortem brain: effect of suicideYogesh Dwivedi, Hooriyah S Rizavi, Hui Zhang, et al.
Neurochemical Research|June 28, 2008
GSK-3beta gene expression in human postmortem brain: regional distribution, effects of age and suicideGhanshyam N Pandey, Yogesh Dwivedi, Hooriyah S Rizavi, et al.
Schizophrenia Research|October 25, 2011
Responses to antipsychotic therapy among patients with schizophrenia or schizoaffective disorder and either predominant or prominent negative symptomsVirginia L Stauffer, Guochen Song, Bruce J Kinon, et al.
The American Journal of Psychiatry|November 8, 2007
Galantamine for the treatment of cognitive impairments in people with schizophreniaRobert W Buchanan, Robert R Conley, Dwight Dickinson, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|May 28, 2005
Brain region specific alterations in the protein and mRNA levels of protein kinase A subunits in the post-mortem brain of teenage suicide victimsGhanshyam N Pandey, Yogesh Dwivedi, Xinguo Ren, et al.
Schizophrenia Research|February 19, 2008
Quetiapine at high doses for the treatment of refractory schizophreniaDouglas L Boggs, Deanna L Kelly, Stephanie Feldman, et al.
Schizophrenia Research|June 14, 2008
Lack of beneficial galantamine effect for smoking behavior: a double-blind randomized trial in people with schizophreniaDeanna L Kelly, Robert P McMahon, Elaine Weiner, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|December 14, 2007
Lower phosphoinositide 3-kinase (PI 3-kinase) activity and differential expression levels of selective catalytic and regulatory PI 3-kinase subunit isoforms in prefrontal cortex and hippocampus of suicide subjectsYogesh Dwivedi, Hooriyah S Rizavi, Tara Teppen, et al.
Current Medical Research and Opinion|January 27, 2011
Cost-effectiveness of olanzapine long-acting injection in the treatment of patients with schizophrenia in the United States: a micro-simulation economic decision modelNicolas M Furiak, Haya Ascher-Svanum, Robert W Klein, et al.
Pageof 12